NASDAQ:MBX • US55287L1017
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MBX BIOSCIENCES INC (MBX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-16 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-12-04 | Goldman Sachs | Initiate | Sell |
| 2025-11-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-04 | TD Cowen | Initiate | Buy |
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-09-24 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-09-23 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-05 | Mizuho | Initiate | Outperform |
| 2025-07-16 | Oppenheimer | Initiate | Outperform |
| 2025-04-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-10 | JMP Securities | Initiate | Market Outperform |
| 2024-10-08 | Guggenheim | Initiate | Buy |
| 2024-10-08 | Stifel | Initiate | Buy |
| 2024-10-08 | JP Morgan | Initiate | Overweight |
| 2024-10-08 | Jefferies | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 3,030.27% | N/A 80.75% | N/A 124.74% | N/A 66.50% | N/A 44.55% | |||||
| EBITDA YoY % growth | -25.105M | -35.154M -40.03% | -67.95M -93.29% | -97.807M -43.94% | N/A -54.33% | N/A -75.06% | N/A -15.41% | N/A 34.56% | N/A 39.45% | N/A 235.20% | N/A 330.01% | N/A 92.31% | |
| EBIT YoY % growth | -25.161M | -35.311M -40.34% | -68.194M -93.12% | -98.055M -43.79% | N/A -55.00% | N/A -46.69% | N/A -16.55% | N/A 41.96% | N/A 48.78% | N/A 303.46% | N/A 200.59% | N/A 76.34% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.41 79.16% | N/A -22.66% | N/A -39.51% | N/A -5.61% | N/A 24.35% | N/A 79.77% | N/A 566.67% | N/A 127.60% | N/A 57.99% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.59 17.12% | -0.67 -15.02% | -0.77 -22.39% | -0.89 -80.73% | -1.05 -78.51% | -1.21 -81.68% | -1.30 -68.98% | -1.39 -57.39% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -30.848M -16.62% | -34.569M -59.54% | -39.988M -68.46% | -45.539M -78.26% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -30.851M -16.29% | -34.94M -60.24% | -39.426M -64.78% | -45.779M -77.47% | N/A | N/A | N/A | N/A |
All data in USD
15 analysts have analysed MBX and the average price target is 62.53 USD. This implies a price increase of 88.1% is expected in the next year compared to the current price of 33.24.
MBX BIOSCIENCES INC (MBX) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of MBX BIOSCIENCES INC (MBX) is -0.59 USD and the consensus revenue estimate is 0 USD.
The consensus rating for MBX BIOSCIENCES INC (MBX) is 82.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.